A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy

OBJECTIVES: To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. METHODS: This is a phase III, randomised, double-blind, multinational, mu...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Ann Rheum Dis
Glavni autori: Choe, Jung-Yoon, Prodanovic, Nenad, Niebrzydowski, Jaroslaw, Staykov, Ivan, Dokoupilova, Eva, Baranauskaite, Asta, Yatsyshyn, Roman, Mekic, Mevludin, Porawska, Wieskawa, Ciferska, Hana, Jedrychowicz-Rosiak, Krystyna, Zielinska, Agnieszka, Choi, Jasmine, Rho, Young Hee, Smolen, Josef S
Format: Artigo
Jezik:Inglês
Izdano: BMJ Publishing Group 2017
Teme:
Clinical and Epidemiological Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5264229/
https://ncbi.nlm.nih.gov/pubmed/26318384
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2015-207764
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items